Pieris Pharmaceuticals Incorporated (NASDAQ:PIRS) had a decrease of 19.7% in short interest. PIRS’s SI was 1.12 million shares in February as released by FINRA. Its down 19.7% from 1.40 million shares previously. With 478,800 avg volume, 2 days are for Pieris Pharmaceuticals Incorporated (NASDAQ:PIRS)’s short sellers to cover PIRS’s short positions. The SI to Pieris Pharmaceuticals Incorporated’s float is 3.47%. The stock decreased 2.71% or $0.24 during the last trading session, reaching $8.63. About 1.00 million shares traded or 42.76% up from the average. Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) has risen 128.81% since February 18, 2017 and is uptrending. It has outperformed by 112.11% the S&P500.
Analysts expect Reis, Inc. (NASDAQ:REIS) to report $0.04 EPS on March, 8.They anticipate $0.06 EPS change or 300.00% from last quarter’s $-0.02 EPS. REIS’s profit would be $458,732 giving it 117.50 P/E if the $0.04 EPS is correct. After having $0.04 EPS previously, Reis, Inc.’s analysts see 0.00% EPS growth. The stock decreased 1.05% or $0.2 during the last trading session, reaching $18.8. About 8,147 shares traded. Reis, Inc. (NASDAQ:REIS) has declined 19.33% since February 18, 2017 and is downtrending. It has underperformed by 36.03% the S&P500.
Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin drugs. The company has market cap of $386.58 million. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. It currently has negative earnings. The firm primarily focuses on the development of four drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; PRS-343, a bispecific protein for oncology diseases; and PRS-332, a bispecific anticalin-antibody fusion protein for oncology diseases.
Among 7 analysts covering Pieris Pharmaceuticals (NASDAQ:PIRS), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Pieris Pharmaceuticals had 16 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, August 13 by Roth Capital. H.C. Wainwright maintained the shares of PIRS in report on Tuesday, February 13 with “Buy” rating. TH Capital initiated the shares of PIRS in report on Wednesday, July 22 with “Buy” rating. The stock has “Buy” rating by H.C. Wainwright on Tuesday, May 30. The company was initiated on Tuesday, July 28 by Oppenheimer. Roth Capital reinitiated the shares of PIRS in report on Friday, August 5 with “Buy” rating. The stock of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) earned “Buy” rating by Roth Capital on Wednesday, July 22. H.C. Wainwright maintained the shares of PIRS in report on Friday, November 10 with “Buy” rating. The firm has “Buy” rating given on Friday, August 11 by H.C. Wainwright. The stock of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) earned “Buy” rating by H.C. Wainwright on Wednesday, December 20.
Among 3 analysts covering Reis (NASDAQ:REIS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Reis had 6 analyst reports since March 23, 2016 according to SRatingsIntel. The firm has “Buy” rating by Canaccord Genuity given on Sunday, November 5. On Tuesday, August 1 the stock rating was maintained by Canaccord Genuity with “Buy”. The firm has “Buy” rating given on Wednesday, March 23 by Canaccord Genuity. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, August 9 report.
Reis, Inc., through its subsidiary, Reis Services, provides commercial real estate market information and analytical tools to real estate professionals in the United States. The company has market cap of $215.60 million. It maintains a proprietary database containing information on commercial properties, including apartment, office, retail, warehouse/distribution, flex/research and development, self-storage, and seniors and student housing properties in the metropolitan markets and neighborhoods. It has a 188 P/E ratio. The company's data is used by real estate investors, lenders, and other professionals to make informed buying, selling, and financing decisions; and debt and equity investors to assess, quantify, and manage the risks of default and loss associated with individual mortgages, properties, portfolios, and real estate backed securities.